A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial).
Campone M, Bachelot T, Treilleux I, Pistilli B, Salleron J, Seegers V, Arnedos M, Loussouarn D, Wang Q, Vanlemmens L, Jimenez M, Rios M, Diéras V, Leroux A, Paintaud G, Rezai K, André F, Lion M, Merlin JL.
Campone M, et al. Among authors: salleron j.
Eur J Cancer. 2021 Oct 19;158:169-180. doi: 10.1016/j.ejca.2021.09.017. Online ahead of print.
Eur J Cancer. 2021.
PMID: 34678678
Free article.